NCT05627297 (AI-HCC) is a clinical trial of CEUS and CEMRI in Hepatocellular Carcinoma, sponsored by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School.

What drugs are being tested in NCT05627297?

Interventions in NCT05627297: CEUS and CEMRI.

What condition does NCT05627297 study?

NCT05627297 studies Hepatocellular Carcinoma.

Is NCT05627297 still recruiting?

NCT05627297 is currently status unknown. Last updated 25 November 2022.

Last reviewed 2022-11-25 · How we verify

NCT05627297: AI-HCC

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Applying Artificial Intelligence to Optimize Early-stage Hepatocellular Carcinoma Treatment Based on Multi-modal Image

Status unknown Last updated 25 November 2022

What this trial tests

trial testing CEUS and CEMRI in Hepatocellular Carcinoma in 200 participants. Status unknown.

Timeline

1 December 2022

Primary endpoint
1 November 2024

1 November 2025

Quick facts

Lead sponsor	The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	200
Start date	1 December 2022
Primary completion	1 November 2024
Estimated completion	1 November 2025
Sites	1 location across China

Drugs / interventions tested

CEUS and CEMRI

Conditions studied

Hepatocellular Carcinoma — all drugs for Hepatocellular Carcinoma →

Sponsor

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Who can join

Eligibility, any sex, with Hepatocellular Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study intends to establish two prognostic models based on contrast-enhanced ultrasound (CEUS) and dynamic enhanced magnetic resonance (DE-MRI) multimodal images: prognostic model of liver cancer patients after hepatectomy and prognostic model of liver cancer patients after radiofrequency ablation. Combined with artificial intelligence imaging omics, traditional imaging omics and clinical information, to predict and compare the prognosis of two different treatment methods for early liver cancer, so as to realize the individual selection of treatment methods for early liver cancer patients

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Translational Bioinformatics Applied to the Study of Complex Diseases.
Casotti MC, Meira DD, Alves LNR, Bessa BGO, et al · · 2023 · cited 12× · PMID 36833346 · DOI 10.3390/genes14020419
Bridging the Gap Between Imaging and Molecular Characterization: Current Understanding of Radiomics and Radiogenomics in Hepatocellular Carcinoma.
Ren L, Chen DB, Yan X, She S, et al · · 2024 · cited 2× · PMID 39619602 · DOI 10.2147/jhc.s423549

Verify or expand the search:

Other recruiting trials for Hepatocellular Carcinoma

Currently open trials in the same condition.

NCT06902246 — Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma · Phase 2 · recruiting
NCT05842174 — Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma · Phase 1, PHASE2 · recruiting
NCT07417397 — Adjuvant TACE in HCC With High-risk Recurrence Factors · Phase 3 · recruiting
NCT07317414 — β-alanine in the Treatment of Advanced Hepatocellular Carcinoma · Phase 2 · recruiting
NCT07148050 — Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimer · Phase 1 · recruiting

Other The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School trials

Trials by the same sponsor.

NCT06966765 — Accelerated vs Standard Approach to Continuous Veno-venous Hemodiafiltration Post-hemoperfusion (ASAP) in Severe Acute D · Phase 3 · not yet recruiting
NCT07403071 — Validating Fish Oil's Role in Alleviating Bortezomib-Induced Neuropathy: A Multi-Method Study Integrating Big Data, Expe · not yet recruiting
NCT07532538 — A Machine Learning-Based Risk Prediction Model for Head and Neck Cancerous Lesions · not yet recruiting
NCT07353645 — KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer · Phase 1, PHASE2 · recruiting
NCT07399574 — Diagnostic Accuracy of A Diquat Quantitative Detection Kit and A Portable Mass Spectrometry System for Quantifying Diqua · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05627297 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Last refreshed: 25 November 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05627297.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing